Effects of pemafibrate on liver fibrosis in patients with MASLD and hypertriglyceridemia: A 2-year retrospective observational study using MR elastography - PubMed
5 hours ago
- #Liver Fibrosis
- #Pemafibrate
- #Hypertriglyceridemia
- Pemafibrate, a selective PPARα modulator, was studied for its effects on liver fibrosis in MASLD patients with hypertriglyceridemia over 2 years.
- The study used MR elastography (MRE) to measure liver stiffness (MRE-LSM) in 25 patients before and after pemafibrate treatment.
- Median MRE-LSM significantly decreased from 3.05 to 2.52 kPa, with 92% of patients showing improvement and 36% meeting responder criteria (≥19% reduction in MRE-LSM).
- Proportion of patients with significant fibrosis decreased from 44.0% to 28.0%.
- Triglyceride levels significantly reduced from 231 to 125 mg/dL.
- Improvements were seen in liver enzyme levels, liver function parameters, and serum fibrosis markers without changes in body weight, glycemic control, or hepatic fat content.
- No treatment discontinuations due to adverse events were reported.
- Findings suggest pemafibrate may have antifibrotic mechanisms independent of weight or fat reduction, supporting its hepatoprotective role.